Related Experiment Videos

[Antibacterial action of clindamycin in chronic, recurrent tonsillitis]

R Müller1, G Wichmann, E Haufe

  • 1Klinik and Poliklinik für Hals-Nasen-Ohren-Heilkunde, Universitätsklinikums Carl Gustav Carus der Technischen Universität Dresden.

Insights

Clindamycin (CAS 18323-44-9) effectively treats recurrent tonsillitis by maintaining therapeutic antibiotic concentrations in serum and tonsil tissue. Dosing of 300 mg three times daily ensures sustained efficacy against bacterial strains.

Area of Science:

  • Pharmacology
  • Infectious Diseases
  • Otolaryngology

Background:

  • Recurrent tonsillitis poses a significant clinical challenge.
  • Understanding antibiotic pharmacokinetics is crucial for effective treatment.

Purpose of the Study:

  • To evaluate the efficacy and pharmacokinetic profile of clindamycin in patients with recurrent tonsillitis.
  • To determine the optimal dosage regimen for clindamycin in this patient population.

Main Methods:

  • Oral administration of 300 mg Sobelin (clindamycin) to 35 patients.
  • Analysis of serum and tonsil tissue concentrations.
  • Determination of Minimal Inhibitory Concentration (MIC) and Minimal Bactericidal Concentration (MBC) for 120 bacterial strains.

Main Results:

  • Clindamycin achieved concentrations above MIC in serum for over 12 hours.
  • Therapeutic concentrations in tonsil tissue (0.6-0.8 µg/g) were sustained for 7-9 hours.
  • The free, unbound portion of clindamycin in serum and tissue demonstrated a bacteriostatic effect up to 6-9 hours post-administration.

Conclusions:

  • Clindamycin (CAS 18323-44-9) is an effective antibiotic for managing acute exacerbations of recurrent tonsillitis.
  • A dosage of 300 mg three times daily is indicated based on achieved serum and tonsil tissue levels.

Related Concept Videos